RDH10

Across TCGA pan-cancer cohorts, RDH10 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RDH10 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RDH10 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RDH10 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where RDH10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.917	0.747	.006	18	view →
LUAD	DFS	Quartile	All	0.413	0.742	.017	5	view →
CCRCC	OS	Median	All	0.982	0.907	.033	2	view →
GBM	OS	Quartile	All	0.288	0.589	.037	1	view →
LSCC	OS	Median	All	1.000	0.800	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RDH10–PDAC (OS)

Open the PDAC breakdown →